181 related articles for article (PubMed ID: 30382297)
1. Effects of magnesium oxide on pharmacokinetics of L-dopa/carbidopa and assessment of pharmacodynamic changes by a model-based simulation.
Kashihara Y; Terao Y; Yoda K; Hirota T; Kubota T; Kimura M; Matsuki S; Hirakawa M; Irie S; Ieiri I
Eur J Clin Pharmacol; 2019 Mar; 75(3):351-361. PubMed ID: 30382297
[TBL] [Abstract][Full Text] [Related]
2. Continuous versus intermittent oral administration of levodopa in Parkinson's disease patients with motor fluctuations: A pharmacokinetics, safety, and efficacy study.
Warren Olanow C; Torti M; Kieburtz K; Leinonen M; Vacca L; Grassini P; Heller A; Heller E; Stocchi F
Mov Disord; 2019 Mar; 34(3):425-429. PubMed ID: 30653246
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, metabolism and safety of deuterated L-DOPA (SD-1077)/carbidopa compared to L-DOPA/carbidopa following single oral dose administration in healthy subjects.
Schneider F; Erisson L; Beygi H; Bradbury M; Cohen-Barak O; Grachev ID; Guzy S; Loupe PS; Levi M; McDonald M; Savola JM; Papapetropoulos S; Tracewell WG; Velinova M; Spiegelstein O
Br J Clin Pharmacol; 2018 Oct; 84(10):2422-2432. PubMed ID: 29959802
[TBL] [Abstract][Full Text] [Related]
4. Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa.
Othman AA; Rosebraugh M; Chatamra K; Locke C; Dutta S
J Parkinsons Dis; 2017; 7(2):275-278. PubMed ID: 28211816
[TBL] [Abstract][Full Text] [Related]
5. Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose.
Heikkinen H; Varhe A; Laine T; Puttonen J; Kela M; Kaakkola S; Reinikainen K
Br J Clin Pharmacol; 2002 Oct; 54(4):363-71. PubMed ID: 12392583
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of Inhaled Levodopa Administered With Oral Carbidopa in the Fed State in Patients With Parkinson's Disease.
Safirstein BE; Ellenbogen A; Zhao P; Henney HR; Kegler-Ebo DM; Oh C
Clin Ther; 2020 Jun; 42(6):1034-1046. PubMed ID: 32482490
[TBL] [Abstract][Full Text] [Related]
7. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic model of oral levodopa and role of carbidopa in parkinsonian patients.
Mizutani Y; Okada Y; Ogawa M; Hasegawa T; Nabeshima T
Biol Pharm Bull; 1995 Dec; 18(12):1729-37. PubMed ID: 8787797
[TBL] [Abstract][Full Text] [Related]
9. Determination of L-dopa, carbidopa, 3-O-methyldopa and entacapone in human plasma by HPLC-ED.
Bugamelli F; Marcheselli C; Barba E; Raggi MA
J Pharm Biomed Anal; 2011 Feb; 54(3):562-7. PubMed ID: 21035976
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of levodopa/carbidopa microtablets in healthy subjects and Parkinson's disease patients.
Senek M; Nyholm D; Nielsen EI
Eur J Clin Pharmacol; 2018 Oct; 74(10):1299-1307. PubMed ID: 29882153
[TBL] [Abstract][Full Text] [Related]
11. Ascorbic acid can alleviate the degradation of levodopa and carbidopa induced by magnesium oxide.
Miyaue N; Kubo M; Nagai M
Brain Behav; 2022 Jul; 12(7):e2672. PubMed ID: 35712877
[TBL] [Abstract][Full Text] [Related]
12. The pharmacokinetic profile of the "first ever" oral dose of levodopa in de novo patients with Parkinson's disease.
Djaldetti R; Rosmarin V; Ziv I; Melamed E
Clin Neuropharmacol; 2001; 24(2):95-8. PubMed ID: 11307044
[TBL] [Abstract][Full Text] [Related]
13. Effect of a macrolide (spiramycin) on the pharmacokinetics of L-dopa and carbidopa in healthy volunteers.
Brion N; Kollenbach K; Marion MH; Grégoire A; Advenier C; Pays M
Clin Neuropharmacol; 1992 Jun; 15(3):229-35. PubMed ID: 1394243
[TBL] [Abstract][Full Text] [Related]
14. Gastroretentive carbidopa/levodopa, DM-1992, for the treatment of advanced Parkinson's disease.
Verhagen Metman L; Stover N; Chen C; Cowles VE; Sweeney M
Mov Disord; 2015 Aug; 30(9):1222-8. PubMed ID: 25847690
[TBL] [Abstract][Full Text] [Related]
15. Concomitant use of magnesium oxide significantly decreases absorption of levodopa preparations in patients with Parkinson's disease.
Miyaue N; Yabe H; Nagai M
Clin Park Relat Disord; 2023; 9():100227. PubMed ID: 38021340
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet(®)), sustained-release carbidopa-levodopa (Sinemet(®) CR), and carbidopa-levodopa-entacapone (Stalevo(®)).
Hsu A; Yao HM; Gupta S; Modi NB
J Clin Pharmacol; 2015 Sep; 55(9):995-1003. PubMed ID: 25855267
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Treatment with Extended-Release Carbidopa-Levodopa (IPX066) in Early and Advanced Parkinson's Disease: A 9-Month Open-Label Extension Trial.
Waters CH; Nausieda P; Dzyak L; Spiegel J; Rudzinska M; Silver DE; Tsurkalenko ES; Kell S; Hsu A; Khanna S; Gupta S
CNS Drugs; 2015 Apr; 29(4):341-50. PubMed ID: 25895021
[TBL] [Abstract][Full Text] [Related]
18. Carbidopa/levodopa extended-release capsules (Rytary).
Med Lett Drugs Ther; 2015 Apr; 57(1467):59-60. PubMed ID: 25897548
[No Abstract] [Full Text] [Related]
19. Dyskinesias in levodopa-carbidopa intestinal gel infusion era: New challenges, new features.
Catalán MJ; Escribano PM; Alonso-Frech F
Mov Disord; 2017 Apr; 32(4):624-625. PubMed ID: 28116835
[No Abstract] [Full Text] [Related]
20. Pharmacokinetic-pharmacodynamic interaction between nebicapone, a novel catechol-o-methyltransferase inhibitor, and controlled-release levodopa/carbidopa 200 mg/50 mg : randomized, double-blind, placebo-controlled, crossover study in healthy subjects.
Vaz-da-Silva M; Loureiro AI; Nunes T; Lopes C; Rocha J; Machado R; Costa R; Torrão L; Falcão A; Wright L; Almeida L; Soares-da-Silva P
Drugs R D; 2008; 9(6):435-46. PubMed ID: 18989992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]